VYJUVEK Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to advancements in gene delivery vectors, improved understanding of collagen-related genetic disorders, expansion of rare disease research programs, early success of topical gene therapy trials, increased regulatory support for breakthrough therapies.

The growth in the forecast period can be attributed to expansion of gene therapy approvals for dermatology, rising demand for durable rare disease treatments, growing investments in topical gene delivery technologies, advancements in redosable therapy platforms, increasing focus on patient-centric genetic therapies. Major trends in the forecast period include increasing adoption of topical gene therapies, rising focus on rare genetic skin disorders, growing use of redosable gene therapy platforms, expansion of targeted wound healing solutions, enhanced emphasis on localized gene delivery.

The rising prevalence of chronic diseases is expected to drive the growth of the Vyjuvek market going forward. Chronic diseases are long-term health conditions that usually persist for a year or more, often requiring ongoing medical care and affecting daily activities. The increasing prevalence of chronic diseases is linked to factors such as aging populations, unhealthy lifestyles, urbanization, and greater exposure to environmental risk factors. Vyjuvek addresses chronic conditions like dystrophic epidermolysis bullosa (DEB) by delivering a functional COL7A1 gene through its topical gel formulation. This enables the production of type VII collagen, strengthening the skin, promoting wound healing, reducing the frequency and severity of chronic wounds, and improving overall quality of life for patients. For instance, in April 2024, Allergy UK, a UK-based national charity, reported that over 21 million people in the UK were affected by allergies, the most commonly reported chronic condition in 2022, with projections indicating that by 2026, half of Europe’s population may experience at least one allergy. Therefore, the rising prevalence of chronic diseases is driving growth in the Vyjuvek market.

Key companies in the Vyjuvek market are focusing on developing innovative therapies, including the first-ever redosable gene therapy, to provide sustained therapeutic effects, address progressive conditions more effectively, and improve patient outcomes. Redosable gene therapy refers to a treatment approach that allows multiple administrations to maintain or enhance the therapy’s effects over time. For instance, in May 2023, Krystal Biotech Inc., a US-based biotechnology company, received FDA approval for Vyjuvek (beremagene geperpavec-svdt), the first-ever redosable gene therapy for DEB. The topical gel restores functional copies of the COL7A1 gene, promoting wound healing and sustained collagen expression, marking the first FDA-approved treatment for DEB that is safe, non-invasive, and suitable for both clinical and home use.

In September 2024, Swixx BioPharma AG, a Switzerland-based specialty commercialization company, partnered with Krystal Biotech Inc. to distribute and commercialize Vyjuvek across Central and Eastern Europe. This collaboration leverages Swixx BioPharma’s regional commercial network alongside Krystal Biotech’s HSV-1 vector-based gene therapy technology to expand patient access to treatment for dystrophic epidermolysis bullosa. Krystal Biotech Inc. specializes in developing gene therapy solutions for rare diseases.

Major companies operating in the vyjuvek market are Krystal Biotech Inc.

North America was the largest region in the vyjuvek market in 202. The regions covered in the vyjuvek market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the vyjuvek market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the vyjuvek market by increasing costs of imported viral vectors, formulation components, sterile manufacturing equipment, and specialized packaging used in topical gene therapy production. North America and Europe are most affected due to reliance on global biotech supply chains and advanced manufacturing inputs. These tariffs are increasing production costs and commercialization expenses. However, they are also supporting domestic gene therapy manufacturing investments, regional sourcing of formulation materials, and long-term resilience of rare disease treatment supply chains.

The vyjuvek market research report is one of a series of new reports that provides vyjuvek market statistics, including vyjuvek industry global market size, regional shares, competitors with a vyjuvek market share, detailed vyjuvek market segments, market trends and opportunities, and any further data you may need to thrive in the vyjuvek industry. This vyjuvek market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Vyjuvek is a topical gene therapy developed to treat dystrophic epidermolysis bullosa (DEB) by delivering functional COL7A1 genes to affected skin cells, promoting sustained collagen production and wound healing. It helps restore skin integrity and accelerate healing in individuals with DEB, targeting the underlying genetic cause, and is the first redosable gene therapy approved for this rare condition.

The primary indications for Vyjuvek include epidermolysis bullosa (EB) and dystrophic epidermolysis bullosa (DEB). Epidermolysis bullosa is a group of rare genetic disorders characterized by fragile skin that blisters easily with minimal trauma, caused by mutations in proteins that hold the skin layers together. Vyjuvek is distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and is used by adult, pediatric, and geriatric patients.

The vyjuvek market consists of sales of topical gels. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.